黄河 - 浙江大学

个人简介

黄河，男，主任医师，博士生导师。现任浙江大学医学院党委书记、副院长。浙江大学医学院附属第一医院骨髓移植中心主任，浙江大学血液病研究所所长。教育背景 1979 - 1984 浙江医科大学临床医学专业获学士学位。 1987 - 1990 浙江医科大学血液病学专业获硕士学位。 1990 - 1993 浙江医科大学血液病专业获博士学位。工作经历 1984 - 1987 住院医师，浙江金华中心医院内科。 1993 - 1997 主治医师，浙江医科大学附属第一医院血液科。 1997 高级访问学者，德国基尔大学血液病理研究所。 1997 – 2000副主任，浙江大学医学院附属第一医院血液科。 1997 – 2016 副所长，浙江大学血液病研究所。 2000 - 至今教授，浙江大学医学院。 2000 - 至今主任，浙江大学医学院附属第一医院骨髓移植中心。 2005 -至今副院长，浙江大学医学院。 2012-至今党委书记，浙江大学医学院。 2016-至今所长，浙江大学血液病研究所。

研究领域

造血干细胞移植与干细胞基础研究；血液病临床与基础研究； CART等免疫细胞治疗

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Tan Y, Xiao H, Wu D, Luo Y, Lan J, Liu Q, Yu K, Shi J, He J, Zheng W, Lai X, Zhu Y, Du K, Ye Y, Zhao Y, Zheng G, Hu Y, Han X, Zheng Y, Wei G, Cai Z, Huang H. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. Oncoimmunology. 2017;6(3):e1277307. 2. Wang Y, Wang Y, Chang T, Huang H*, Yee JK. Integration-defective lentiviral vector mediates efficient gene editing through homology-directed repair in human embryonic stem cells. Nucleic Acids Res. 2017;45(5):e29. 3. Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A, Zhang H, Cai Z, Xiao L, Huang H*. Potent anti-leukemia activities of chimeric antigen receptor modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017;23(13):3297-3306. 4. Xu Y, Shan W, Li X, Wang B, Liu S, Wang Y, Long Y, Tie R, Wang L, Cai S, Zhang H, Lin Y, Zhang M, Zheng W, Luo Y, Yu X, Yee JK, Ji J, Huang H*. A synthetic three-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells. J Hematol Oncol. 2016;9(1):102. 5. Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H*. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016;9(1):70. 6. Hu Y, Cui Q, Luo C, Luo Y, Shi J, Huang H*. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications. Blood Rev. 2016;30(3):179-188. 7. Hu K, Gu Y, Lou L, Liu L, Hu Y, Wang B, Luo Y, Shi J, Yu X, Huang H*. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway. J Hematol Oncol. 2015;8(1):1. 8. Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H*. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014;124(17):2735-2743. 9. Wu K, Wang Y, He Y, Hu Y, Fu H, Sheng L, Wang B, Fu S, Huang H*. Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment. Leukemia. 2014;28(1):206-210. 10. Wang L, Xiao H, Zhang X, Wang C, Huang H*.The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. J Hematol Oncol. 2014;7:61. 11. Hu Y, Cui Q, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Fu H, Liu L, Fu S, Yu X, Huang H*. Decitabine facilitates the generation and immunosuppressive function of regulatory gammadelta T cells derived from human peripheral blood mononuclear cells. Leukemia. 2013;27(7):1580-1585. 12. Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica. 2012;97 (12):1804-1812. 13. Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, Yu X, Cai Z, Lin M, Ye X, Huang H*. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2011;117(19):5257-5260. 14. Yu J, Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C*, Huang H*. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 2010;291(2):177-186. 15. Luo Y, Lai X, Tan Y, Shi J, Zhao Y, Han X, Zheng G, Zhu X, Sun J, Zheng Y, Wu G, He J, Chen S, Jin A, Xie W, Ye X, Cai Z, Lin M, Huang H*. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia. 2009;23(6):1171-1174.